OncLive TV

Naval G. Daver, MD, discusses the results of a phase Ib/II study that evaluated the combination of azacitidine and nivolumab (Opdivo) in patients with relapsed/refractory acute myeloid leukemia.

Claire Manuszak, BS, discusses a phase I study (NCT03495323) with prexasertib (LY2606368) and LY3300054 in ovarian cancer.

Stephen J. Freedland, MD, discusses the importance of standardizing prostate-specific antigen testing in prostate cancer.

Eileen Connolly, MD, PhD, discusses the possible benefit of postmastectomy radiation for patients with breast cancer.

David Ritchie, MD, PhD, discusses immunological recovery with venetoclax (Venclexta) and ibrutinib (Imbruvica) in mantle cell lymphoma.

Michael L. Grossbard, MD, discusses the utility of PI3K inhibitors in follicular lymphoma.

Noopur Raje, MD, discusses the utility of belantamab mafodotin in the treatment of patients with multiple myeloma.

David F. McDermott, MD, discusses the research behind combining VEGF inhibitors with PD-1/PD-L1 inhibitors in renal cell carcinoma treatment.

Michael R. Charlton, MD, MBBS, discusses the emergence of biomarkers in hepatocellular carcinoma.

Shella Saint Fleur-Lominy, MD, PhD, discusses the effects ruxolitinib has on symptom burden in patients with myeloproliferative neoplasms.

Andrew J. Armstrong, MD, discusses the utility of liquid biopsies in metastatic castration-resistant prostate cancer.

Leisha A. Emens, MD, PhD, discusses the incidence and treatment of immune-related adverse events in ovarian cancer.

Michael Choi, MD, discusses frontline treatment considerations in chronic lymphocytic leukemia.

Jonathan W. Goldman, discusses the impact of liquid biopsies in lung cancer.

Betsy O’Donnell, MD, discusses unanswered questions in multiple myeloma.

Lori Brisbin, discusses using Trapelo, an automated tool to track precision medicine guidelines in various cancers, in patients with ovarian cancer.

Amir Khan, MD, discusses a large retrospective database analysis on colorectal cancer and gastric cancer presented at the 2020 Gastrointestinal Cancers Symposium.

Sara M. Tolaney, MD, MPH, discusses novel approaches in treating patients with HER2-positive breast cancer.

John M. Pagel, MD, PhD, discusses time-limited therapy in chronic lymphocytic leukemia.

Amin J. Mirhadi, MD, discusses patient populations of lung cancer who should be treated with radiation therapy.

Chung-Han Lee, MD, PhD, discusses treatment options for patients with metastatic renal cell carcinoma.

Matthew H.G. Katz, MD, FACS, discusses the utility of preoperative chemotherapy for patients with resectable pancreatic cancer.

William L. Dahut, MD, senior investigator and section chief, Genitourinary Malignancies Branch, head, Prostate Cancer Clinical Research Section, clinical director and scientific director for clinical research, Center for Cancer Research, National Cancer Institute (NCI), discusses an NCI-led study that is using screening to detect prostate cancer.

Jean Lopategui, MD, associate professor of pathology and director of Translational Genomics and of the Molecular Genetics Pathology Fellowship at Cedars-Sinai, discusses the implications of genomic sequencing in lung cancer.

Kathleen Moore, MD, director, Oklahoma TSET Phase I Clinical Trials Program, and associate professor, Section of Gynecologic Oncology, Jim and Christy Everest Endowed Chair in Cancer Research, director, Gynecologic Oncology Fellowship Program, associate director of Clinical Research, and medical director of the Clinical Trials Office, at Stephenson Cancer Center, discusses the role of mirvetuximab soravtansine in platinum-resistant ovarian cancer.

Jean Wright, MD, discusses key strategies in using radiation therapy to treat patients with breast cancer.

Vincent Chung, MD, discusses the effect of gemcitabine, nab-paclitaxel (Abraxane), metformin, and dietary supplements on patients with pancreatic cancer.

Aaron Goodman, MD, hematologist/oncologist and assistant professor of medicine at the University of California, San Diego, discusses the role of transplant in patients with T-cell lymphomas.

Andrew Branagan, MD, discusses the research tandem transplants in patients with high-risk multiple myeloma.

Ronald B. Natale, MD, medical director, Clinical Lung Cancer Program and assistant clinical professor of medicine, Cedars-Sinai, discusses the utility of PD-L1 expression and tumor mutational burden (TMB) in lung cancer.